Business Wire

Guidewire Announces Availability of its First P&C Insurance CRM Applications for Salesforce Financial Services Cloud

14.5.2018 15:55:00 EEST | Business Wire | Press release

Share

Guidewire Software, Inc. (NYSE: GWRE), a provider of software products to Property and Casualty (P&C) insurers, today announced its first two digital applications for Salesforce Financial Services Cloud designed to deliver Customer Relationship Management (CRM) optimized for the unique needs of the P&C insurance industry. The applications, Guidewire ProducerEngage™ for Salesforce Financial Services Cloud and Guidewire ServiceRepEngage™ for Salesforce Financial Services Cloud, will empower captive agents and customer service representatives to better engage with their customers through stronger alignment between marketing, sales, and service, while surfacing actionable insights through the integration of policyholder data between Guidewire and Salesforce applications.

ProducerEngage for Salesforce Financial Services Cloud gives captive agents robust sales and self-service tools and current policyholder information, so they can maximize the value of their relationships with their customers. With ProducerEngage, agents can interact more efficiently with reduced manual processes since they no longer need to switch between systems or re-key information. ServiceRepEngage for Salesforce Financial Services Cloud helps customer service representatives and call center agents deliver the informed and empowered service that today’s policyholders expect by providing an easy-to-navigate application that provides a holistic view of policyholders and their accounts, helping them to more effectively service and retain their customers.

“Insurers, especially those with captive or employed agents, are investing in digital capabilities that simplify the process of knowing and managing the customer relationship well beyond the functionality found in standard core applications,” said Karlyn Carnahan, Head of Celent’s Property Casualty practice in the Americas. “Guidewire’s new products, which have been specifically designed to optimize the functionality provided by Salesforce, enable carriers to significantly expand their ability to support the agents and optimize a differentiated customer relationship.”

These Guidewire Digital applications reflect significant R&D engineering investment since the Guidewire and Salesforce collaboration was announced in September 2017, and will benefit P&C insurers by providing a consistent and integrated 360-degree view of their customers across the Guidewire and Salesforce platforms. With a view to reducing future total cost of ownership, this productized integration between Salesforce and Guidewire enables insurers to be confident that they will benefit from future product enhancements, with the benefits of the Salesforce platform.

Having complete customer visibility is a critical need for insurers running customer-centric operations and serves as a foundation for future joint capabilities, such as optimizing leads, and increasing customer retention. These applications bring together the strengths of the world’s #1 CRM platform and Guidewire’s P&C insurance industry platform for high-quality insurance experiences, operations, and data optimized for the unique needs of P&C insurance, and empower insurers to meet heightened customer expectations.

“Technology has vastly changed the way customers expect to interact with insurers, so these companies need to provide more personalized and engaging experiences to compete,” said Rohit Mahna, SVP and GM of Financial Services, Salesforce. “Guidewire understands this imperative, and we’re excited to provide our mutual customers with the combined power of Salesforce Financial Services Cloud and Guidewire’s deep industry-specific capabilities.”

"Insurers are recognizing the importance of customer centricity and front-office digital enablement," said Ayan Sarkar, Principal Business Owner - Digital, Guidewire Software. "We are excited to collaborate with Salesforce, a formidable authority in cloud-based CRM, and bring together our Engage applications integrated into their CRM platform. This productized integration between our platforms will help insurers transform the distribution and service of their products, to the benefit of both their businesses and their policyholders."

Salesforce, Financial Services Cloud and others are trademarks of salesforce.com, inc.

About Guidewire Software

Guidewire delivers the software that Property and Casualty (P&C) insurers need to adapt and succeed in a time of rapid industry change. We combine three elements – core operations, data and analytics, and digital engagement – into a technology platform that enhances insurers’ ability to engage and empower their customers and employees. More than 300 P&C insurers around the world have selected Guidewire. For more information, please visit www.guidewire.com. Follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Guidewire Software, Inc.
Diana Stott, +1-650-356-4941
Director, Communications
dstott@guidewire.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye